Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines

Mazziotti, Gherardo; Formenti, Anna Maria; Adler, Robert A.; Bilezikian, John P.; Grossman, Ashley; Sbardella, Emilia; Minisola, Salvatore; Giustina, Andrea

doi:10.1007/s12020-016-1146-8

Cited by 98 publications

(42 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Teriparatide (recombinant human parathyroid hormone 1-34) is used in the treatment of postmenopausal OP with a high risk of fracture. 51 Teriparatide has a serious side-effect warning, because high doses of teriparatide can upregulate the occurrence of osteosarcomas in rats. 52 On the other hand, osteoclasts could be set as an essential target for OP treatment.…”

Section: Discussionmentioning

confidence: 99%

A bone-resorption surface-targeting nanoparticle to deliver anti-miR214 for osteoporosis therapy

Cai

Yang

Zhang

et al. 2017

IJN

View full text Add to dashboard Cite

With increasing fracture risks due to fragility, osteoporosis is a global health problem threatening postmenopausal women. In these patients, osteoclasts play leading roles in bone loss and fracture. How to inhibit osteoclast activity is the key issue for osteoporosis treatment. In recent years, miRNA-based gene therapy through gene regulation has been considered a potential therapeutic method. However, in light of the side effects, the use of therapeutic miRNAs in osteoporosis treatment is still limited by the lack of tissue/cell-specific delivery systems. Here, we developed polyurethane (PU) nanomicelles modified by the acidic peptide Asp 8 . Our data showed that without overt toxicity or eliciting an immune response, this delivery system encapsulated and selectively deliver miRNAs to OSCAR + osteoclasts at bone-resorption surface in vivo. With the Asp 8 -PU delivery system, anti-miR214 was delivered to osteoclasts, and bone microarchitecture and bone mass were improved in ovariectomized osteoporosis mice. Therefore, Asp 8 -PU could be a useful bone-resorption surface-targeting delivery system for treatment of osteoclast-induced bone diseases and aging-related osteoporosis.

show abstract

Section: Discussionmentioning

confidence: 99%

A bone-resorption surface-targeting nanoparticle to deliver anti-miR214 for osteoporosis therapy

Cai

Yang

Zhang

et al. 2017

IJN

View full text Add to dashboard Cite

show abstract

“…Several chapters are devoted to primary or secondary states of altered PTH secretion and during glucocorticoid treatment [7].…”

Section: Prefacementioning

confidence: 99%

Preliminaries

2018

Frontiers of Hormone Research

View full text Add to dashboard Cite

Bibliographic Indices. This publication is listed in bibliographic services, including Current Contents ® and PubMed/MEDLINE.Disclaimer. The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the book is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.Drug Dosage. The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

show abstract

“…They suppress IGF-1, a hormone crucial for general growth [12] and bone and collagen formation [13]. They inhibit calcium absorption from the intestine.…”

Section: Mechanism Of Glucocorticoid Actionmentioning

confidence: 99%

Advances in treatment of glucocorticoid-induced osteoporosis

Hsu

Nanes

2017

Current Opinion in Endocrinology, Diabetes &Amp; Obesity

View full text Add to dashboard Cite

Purpose of Review To summarize monitoring, prevention, and treatment options of glucocorticoid-induced osteoporosis for patients on chronic glucocorticoid therapy. Recent Findings Recent meta-analyses highlight the efficacy of bisphosphonate use in improving bone mineral density and in reducing vertebral fractures in the setting of long term glucocorticoid use. A new study has now shown that alendronate also reduces the risk of hip fracture in glucocorticoid use. Emerging data indicate that teriparatide and denosumab also reduce the risk of osteoporotic fracture in glucocorticoid-induced osteoporosis. Summary Glucocorticoid use is a leading cause of secondary osteoporosis; however, patients at risk of glucocorticoid-induced osteoporosis are often not evaluated or treated in a timely manner. Patients on a dose equivalent of 2.5mg prednisone or greater for 3 months or longer duration should have their fracture risk assessed. Those at moderate or high risk should start bisphosphonate therapy, or if contraindicated, a second line agent such as teriparatide or denosumab.

show abstract

Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines

Cited by 98 publications

References 85 publications

A bone-resorption surface-targeting nanoparticle to deliver anti-miR214 for osteoporosis therapy

A bone-resorption surface-targeting nanoparticle to deliver anti-miR214 for osteoporosis therapy

Preliminaries

Advances in treatment of glucocorticoid-induced osteoporosis

Contact Info

Product

Resources

About